Antoxis
Aberdeen
About Antoxis
Antoxis is a pre-clinical drug discovery company that utilises its patented Kromex™ chemistry scaffold to generate New Chemical Entities (NCE) targeting a number of high-value clinical indications. This innovative Kromex™ scaffold is developed from an in-depth knowledge of free radical biology and redox chemistry and protects over 100 Million compounds. This Kromex™ NCE library contains molecules with potential to modulate a broad spectrum of oxidative stress associated diseases and conditions that involve mitochondrial dysfunction. Antoxis is currently focusing its efforts on a sub-set of Kromex™ compounds that show rapid mito-targeting (minutes), potent mito-activity (100 fold greater than competing agents) and long term stability within the cell (48 h). With patent grants in a number of key territories including the US, Antoxis lead compounds can be separated into two potent drug families: (i) Oxidative stress inhibitors associated with mitochondrial dysfunction Proxison™ - a powerful co-treatment that maximizes the clinical outcomes of regenerative medicine therapies (cell quality and cell numbers). Proxison™ compounds are also being developed for the treatment of neurodegenerative diseases (ii) Mitochondrial redox modulators for the (co-therapy) treatment of drug-resistant cancer Oncamex™ shows drug synergy with a number of cancer therapies and when used in combination can reverse cell line resistance to treatments
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $423.6K
- Funding stage: Seed
- Last round: Seed (Mar 2009)
- Website: antoxis.com
- Phone: +44(0)1224 438571
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/antoxis-2889879 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.